AI Diagnostic Platform Company Noul Releases 2022-2023 Sustainability Report

Publish the 3rd sustainability report and self-disclose to DART electronic disclosure system Disclose key achievement of 5 sustainability focus areas for communicating with stakeholders Systematize Noul Hybrid Business Model that creates both business and social values in an integrated way

YONGIN, South Korea, June 27, 2023 /PRNewswire/ — Noul Co., Ltd., (376930.KR), an Artificial Intelligence (AI) based decentralized diagnostic platform company, has released its 2022-2023 Sustainability Report, including corporate efforts and achievements in implementing sustainability. Noul has also self-disclosed the report to the DART electronic disclosure system on July 27. Since 2020, Noul has issued a sustainability report every year, transparently disclosing to the stakeholders corporate activities and performances in the economic, social and environmental sector according to the company’s growth stage.


2022-2023 Noul Sustainability Report

As the range of stakeholders expands due to KOSDAQ listing and product’s global market entry, Noul defined 5 Sustainability Focus Areas: Improvement in Access to Healthcare, Compliance, Ethics and Risk Management, Sound and Sustainable Governance, Responsible and Inclusive Workplace, Protecting the Planet, and disclosed its achievements in each area to strengthen communication with key stakeholders.

Among the 5 Sustainability Focus Areas, there were notable achievements in the area of ‘Improvement in Access to Healthcare’ related to products and businesses. Regarding the miLab™ Platform, there was progress in the development of two new cartridge models for blood cell morphology analysis (miLab™ Cartridge BCM) and cervical cell analysis (miLab™ Cartridge CER), as well as the acquisition of CE marking (IVDD DoC) for these cartridges. In terms of business, major achievements were entering markets into 10 countries in Africa, Latin America, and Europe, and receiving research funds from the RIGHT Foundation to commercialize malaria diagnostic platforms. In addition, selecting a project to explore novel cancer profiling technology, and signing research partnerships with organizations under the Cameroonian and Ghanaian governments were also mentioned as the achievements.

Furthermore, what stands out in the report is Noul Hybrid Business Model, which explains how Noul’s products can solve problems faced by customers and markets, and what utility they can give. This model has a meaning in offering a structured view of how Noul’s business activities contribute to social impact generation.

David Lim, a CEO of Noul, said,  “The value of sustainability that we have pursued from day one has now moved beyond our initial aspirations to become the principle of our organizational operations, the standard of our HR policy, the driver of our technology innovation, and the strategy of our business growth at every level of our organization. Noul will keep integrating business and social values in balance and plan to create achievements for the next level of growth. Building on such achievements, we will make tangible results in global sales and business expansion from 2023.”

Meanwhile, Noel makes management decisions based on the articles of association based on the philosophy of sustainability. By disclosing annual sustainability improvement plans and implementation results through sustainability report, Noul also strives to communicate responsibly with stakeholders, including investors, shareholders, customers, cooperative partners, and employees, who are participating in Noul’s mission.

The 2022-2023 Noul Sustainability Report can be downloaded from the Noul website.

#ESG #ESG Report #Environmental Social Governance #Sustainability #Sustainability Report #Noul #miLab #Diagnosis #AI Diagnosis #Diagnostic Platform #Diagnostic Solution #Healthcare Access

About Noul

Noul, an AI-based decentralized diagnostic platform company that develops and manufactures next-generation diagnostic platforms, was established in December 2015 based on the mission of ‘explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities’. At Noul, experts from various fields including bio, AI, S/W, mechanics, and manufacturing are gathered to solve important human health problems.

Noul’s representative product, miLab™ Diagnostic Platform, is a decentralized diagnostic platform that provides on-site diagnosis. It is a solution that differentiates diagnostic convenience while maintaining the accuracy of microscopic diagnosis procedures which is known as the gold standard in blood diagnostics. From sample preparation to imaging and AI analysis, miLab™ performs the microscopic diagnosis procedures into a fully automated benchtop platform, and provides an accurate analysis in 15 minutes using just 5μl of blood.

Noul has strived to mature into a company grounded in the philosophy of sustainability since its foundation. Taking sustainability into its central philosophy of corporate management, Noul focuses on internalizing sustainability values in business practices, technology and product developments, and organizational operations. The sustainability of Noul is to comply with ethical and legal standards as a corporate citizen and to balance economic, social, and environmental values on the responsible relationships with stakeholders.

Website https://noul.kr/en/

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.